Business Context and Reporting Period
This Form 6-K filing by Biodexa Pharmaceuticals Plc covers the month of June 2026. The report addresses a corporate governance event rather than financial performance, specifically the adjournment of the Company's Annual General Meeting (AGM) held on June 17, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and contains no financial statements or operational data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the procedural adjournment of the AGM due to a lack of quorum.
Guidance, Outlook, and Management Commentary
- Meeting Rescheduling: The AGM has been rescheduled to June 30, 2026, at 11:00 a.m. (London time).
- Location: The meeting will be held at the Company's registered office at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ.
- Reason for Adjournment: The original meeting on June 17, 2026, could not proceed due to a lack of quorum.
- Exhibits: A press release detailing this announcement is attached as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the new AGM date of June 30, 2026, to ensure participation or voting instructions are updated.
- Confirm the physical location of the rescheduled meeting at the Cardiff registered office.
- Review the attached press release (Exhibit 99.1) for any additional details on the agenda or proxy voting requirements for the rescheduled date.
- Note that this filing does not contain financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial data.